Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar Therapeutics also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Larimar Therapeutics, based in the Philadelphia area, is committed to discovering and developing treatments for complex rare diseases, with an initial focus on Friedreich’s ataxia. Its proprietary protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that currently have ineffective or no treatments available.
Total Funding: $250.2 M
Funding Stage: Funded
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2016
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Larimar Therapeutics
Associate Director, Bioanalytical Development
Bala Cynwyd, Pennsylvania
Neurobiology Scientist
Philadelphia, Pennsylvania
Drug Substance Manufacturing Specialist / Sr. Specialist
Bala Cynwyd, Pennsylvania
Specialist / Sr. Specialist Analytical Science
Bala Cynwyd, Pennsylvania
